Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations

Thorac Cancer. 2021 Jun;12(11):1791-1792. doi: 10.1111/1759-7714.13997. Epub 2021 May 11.

Authors

Fabrizio Citarella¹, Marco Russano¹, Giuseppe Perrone², Bruno Vincenzi¹, Giuseppe Tonini¹, Daniele Santini¹

Affiliations

¹ Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
² Pathology Department, Campus Bio-Medico University, Rome, Italy.

No abstract available

Publication types

Letter
Comment

MeSH terms

Afatinib
Carcinoma, Non-Small-Cell Lung*
ErbB Receptors / genetics
Humans
Lung Neoplasms*
Mutation

Substances

Afatinib
EGFR protein, human
ErbB Receptors